David Lassen Shares Insights on Prime/MRx Analysis on GLP-1 for Weight Loss in New Video

October 31, 2023

Earlier this year, Prime Therapeutics/Magellan Rx (Prime/MRx) announced a real-world analysis of glucagon-like peptide-1 agonist (GLP-1a) drugs for weight loss, which found low adherence and increased cost among individuals taking the drug after one year.

WATCH: David Lassen, Chief Clinical Officer at Prime/MRx, shares additional insights on this study

As GLP-1a drugs continue to alter the health care landscape, Prime/MRx subject matter experts will continue keep the pulse on this dynamic trend with trusted data and insights. Check our news page for regular updates.

Related news

Perspectives

April 17, 2024

AMCP 2024: Behind the research with YuQian Liu

Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier

Perspectives

April 16, 2024

AMCP 2024: Behind the research with Jacob LaRue and Timothy O’Shea

Ahead of their session, Jacob and Timothy share how Prime/MRx is working alongside providers like Horizon Blue Cross Blue Shield of New Jersey to manage drug waste and rein in spend for specialty drugs without therapeutic impact to patients

Perspectives

April 15, 2024

Oncology Insights: Cancer treatment is personal

Precision medicine, or personalized medicine, uses genes or proteins to diagnose or treat disease. This medical care design has significantly impacted oncology and grew out of a need to improve and individualize patient treatments